Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 1.58
NPSP's Cash to Debt is ranked higher than
59% of the 1493 Companies
in the Global Biotechnology industry.

( Industry Median: 48.04 vs. NPSP: 1.58 )
NPSP' s 10-Year Cash to Debt Range
Min: 0.22   Max: 96771
Current: 1.58

0.22
96771
Equity to Asset 0.46
NPSP's Equity to Asset is ranked higher than
61% of the 1113 Companies
in the Global Biotechnology industry.

( Industry Median: 0.66 vs. NPSP: 0.46 )
NPSP' s 10-Year Equity to Asset Range
Min: -1.62   Max: 0.99
Current: 0.46

-1.62
0.99
F-Score: 4
Z-Score: 16.13
M-Score: -1.90
WACC vs ROIC
2.36%
19.56%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) 6.98
NPSP's Operating margin (%) is ranked higher than
87% of the 1195 Companies
in the Global Biotechnology industry.

( Industry Median: -79.37 vs. NPSP: 6.98 )
NPSP' s 10-Year Operating margin (%) Range
Min: -4401.9   Max: 47.29
Current: 6.98

-4401.9
47.29
Net-margin (%) 0.49
NPSP's Net-margin (%) is ranked higher than
83% of the 1195 Companies
in the Global Biotechnology industry.

( Industry Median: -72.15 vs. NPSP: 0.49 )
NPSP' s 10-Year Net-margin (%) Range
Min: -4031.2   Max: 30.05
Current: 0.49

-4031.2
30.05
ROE (%) 0.92
NPSP's ROE (%) is ranked higher than
86% of the 1371 Companies
in the Global Biotechnology industry.

( Industry Median: -28.22 vs. NPSP: 0.92 )
NPSP' s 10-Year ROE (%) Range
Min: -336.52   Max: 15.8
Current: 0.92

-336.52
15.8
ROA (%) 0.37
NPSP's ROA (%) is ranked higher than
86% of the 1497 Companies
in the Global Biotechnology industry.

( Industry Median: -22.65 vs. NPSP: 0.37 )
NPSP' s 10-Year ROA (%) Range
Min: -63.13   Max: 14.73
Current: 0.37

-63.13
14.73
ROC (Joel Greenblatt) (%) 29.69
NPSP's ROC (Joel Greenblatt) (%) is ranked higher than
93% of the 1457 Companies
in the Global Biotechnology industry.

( Industry Median: -358.68 vs. NPSP: 29.69 )
NPSP' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -3684.06   Max: 273.86
Current: 29.69

-3684.06
273.86
Revenue Growth (3Y)(%) 1.30
NPSP's Revenue Growth (3Y)(%) is ranked higher than
76% of the 810 Companies
in the Global Biotechnology industry.

( Industry Median: 1.30 vs. NPSP: 1.30 )
NPSP' s 10-Year Revenue Growth (3Y)(%) Range
Min: -47.8   Max: 90.4
Current: 1.3

-47.8
90.4
EBITDA Growth (3Y)(%) -65.80
NPSP's EBITDA Growth (3Y)(%) is ranked higher than
53% of the 856 Companies
in the Global Biotechnology industry.

( Industry Median: -2.60 vs. NPSP: -65.80 )
NPSP' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -75.6   Max: 87.7
Current: -65.8

-75.6
87.7
EPS Growth (3Y)(%) -36.20
NPSP's EPS Growth (3Y)(%) is ranked higher than
58% of the 824 Companies
in the Global Biotechnology industry.

( Industry Median: -4.80 vs. NPSP: -36.20 )
NPSP' s 10-Year EPS Growth (3Y)(%) Range
Min: -86.9   Max: 278
Current: -36.2

-86.9
278
» NPSP's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

NPSP Guru Trades in Q2 2014

Joel Greenblatt 12,104 sh (New)
Louis Moore Bacon 25,000 sh (New)
Eric Mindich 408,141 sh (New)
Mariko Gordon 15,986 sh (+7.81%)
Louis Moore Bacon 30,000 sh (unchged)
John Burbank Sold Out
Jim Simons Sold Out
RS Investment Management Sold Out
Pioneer Investments 253,897 sh (-7.42%)
Columbia Wanger 1,736,720 sh (-37.33%)
» More
Q3 2014

NPSP Guru Trades in Q3 2014

Paul Tudor Jones 8,388 sh (New)
Mariko Gordon 16,864 sh (+5.49%)
Pioneer Investments 418,971 sh (unchged)
Louis Moore Bacon Sold Out
Joel Greenblatt Sold Out
Eric Mindich Sold Out
Columbia Wanger 1,257,320 sh (-27.60%)
» More
Q4 2014

NPSP Guru Trades in Q4 2014

Joel Greenblatt 5,743 sh (New)
Ken Fisher 9,350 sh (New)
Pioneer Investments 524,878 sh (+25.28%)
Paul Tudor Jones 10,016 sh (+19.41%)
Mariko Gordon Sold Out
Columbia Wanger 1,217,320 sh (-3.18%)
» More
Q1 2015

NPSP Guru Trades in Q1 2015

Ken Fisher Sold Out
Pioneer Investments Sold Out
Joel Greenblatt Sold Out
Columbia Wanger Sold Out
Paul Tudor Jones Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with NPSP

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about NPS Pharmaceuticals Inc

Shire Set To Acquire NPS Pharmaceuticals for $5.2 Billion
Following a number of pharma mergers last year, which included the likes of Actavis and Forest Laboratories, Shire (SHPG) announced on Jan. 11 that it is acquiring NPS Pharmaceuticals (NPSP) for $5.2 billion. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 3064.70
NPSP's P/E(ttm) is ranked higher than
86% of the 1656 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. NPSP: 3064.70 )
NPSP' s 10-Year P/E(ttm) Range
Min: 8.92   Max: 3064.67
Current: 3064.7

8.92
3064.67
Forward P/E 21.19
NPSP's Forward P/E is ranked higher than
93% of the 1656 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. NPSP: 21.19 )
N/A
PE(NRI) 2298.50
NPSP's PE(NRI) is ranked higher than
87% of the 1656 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. NPSP: 2298.50 )
NPSP' s 10-Year PE(NRI) Range
Min: 9.13   Max: 2298.5
Current: 2298.5

9.13
2298.5
P/B 37.37
NPSP's P/B is ranked lower than
55% of the 1656 Companies
in the Global Biotechnology industry.

( Industry Median: 6.60 vs. NPSP: 37.37 )
NPSP' s 10-Year P/B Range
Min: 16.26   Max: 38.66
Current: 37.37

16.26
38.66
P/S 22.99
NPSP's P/S is ranked higher than
66% of the 1656 Companies
in the Global Biotechnology industry.

( Industry Median: 40.71 vs. NPSP: 22.99 )
NPSP' s 10-Year P/S Range
Min: 1.6   Max: 136.3
Current: 22.99

1.6
136.3
EV-to-EBIT 327.29
NPSP's EV-to-EBIT is ranked higher than
89% of the 1656 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. NPSP: 327.29 )
NPSP' s 10-Year EV-to-EBIT Range
Min: -2633.6   Max: 38665.5
Current: 327.29

-2633.6
38665.5
Current Ratio 5.89
NPSP's Current Ratio is ranked higher than
78% of the 1464 Companies
in the Global Biotechnology industry.

( Industry Median: 4.49 vs. NPSP: 5.89 )
NPSP' s 10-Year Current Ratio Range
Min: 0.52   Max: 96.48
Current: 5.89

0.52
96.48
Quick Ratio 5.10
NPSP's Quick Ratio is ranked higher than
76% of the 1464 Companies
in the Global Biotechnology industry.

( Industry Median: 4.23 vs. NPSP: 5.10 )
NPSP' s 10-Year Quick Ratio Range
Min: 0.52   Max: 96.48
Current: 5.1

0.52
96.48
Days Inventory 1.00
NPSP's Days Inventory is ranked higher than
100% of the 1656 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. NPSP: 1.00 )
NPSP' s 10-Year Days Inventory Range
Min: 5.35   Max: 1524.3
Current: 1

5.35
1524.3
Days Sales Outstanding 65.70
NPSP's Days Sales Outstanding is ranked higher than
83% of the 1656 Companies
in the Global Biotechnology industry.

( Industry Median: 141.98 vs. NPSP: 65.70 )
NPSP' s 10-Year Days Sales Outstanding Range
Min: 1.55   Max: 331.79
Current: 65.7

1.55
331.79

Valuation & Return

vs
industry
vs
history
Price/Net Cash 270.41
NPSP's Price/Net Cash is ranked higher than
59% of the 1656 Companies
in the Global Biotechnology industry.

( Industry Median: 440.10 vs. NPSP: 270.41 )
NPSP' s 10-Year Price/Net Cash Range
Min: 1.76   Max: 2993
Current: 270.41

1.76
2993
Price/Net Current Asset Value 49.97
NPSP's Price/Net Current Asset Value is ranked higher than
59% of the 1656 Companies
in the Global Biotechnology industry.

( Industry Median: 48.94 vs. NPSP: 49.97 )
NPSP' s 10-Year Price/Net Current Asset Value Range
Min: 1.71   Max: 198
Current: 49.97

1.71
198
Price/Tangible Book 47.39
NPSP's Price/Tangible Book is ranked lower than
58% of the 1656 Companies
in the Global Biotechnology industry.

( Industry Median: 10.70 vs. NPSP: 47.39 )
NPSP' s 10-Year Price/Tangible Book Range
Min: 1.54   Max: 41.03
Current: 47.39

1.54
41.03
Price/Median PS Value 3.87
NPSP's Price/Median PS Value is ranked higher than
65% of the 1656 Companies
in the Global Biotechnology industry.

( Industry Median: 3.50 vs. NPSP: 3.87 )
NPSP' s 10-Year Price/Median PS Value Range
Min: 0.31   Max: 64.42
Current: 3.87

0.31
64.42
Price/Graham Number 99.93
NPSP's Price/Graham Number is ranked higher than
86% of the 1656 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. NPSP: 99.93 )
NPSP' s 10-Year Price/Graham Number Range
Min: 1.33   Max: 56.52
Current: 99.93

1.33
56.52
Earnings Yield (Greenblatt) 0.30
NPSP's Earnings Yield (Greenblatt) is ranked higher than
86% of the 1456 Companies
in the Global Biotechnology industry.

( Industry Median: -5.50 vs. NPSP: 0.30 )
NPSP' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.1   Max: 22.1
Current: 0.3

0.1
22.1

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:NPM.Germany,
NPS Pharmaceuticals Inc was incorporated in Utah in 1986 and reincorporated in Delaware in 1992. The Company is a biopharmaceutical company, which is focused on the development of new treatment options for patients with rare gastrointestinal and endocrine disorders and serious unmet medical needs. The Company's clinical programs involve two proprietary therapeutic proteins to restore or replace biological function: GATTEX(tm) (teduglutide) and Natpara (parathyroid hormone 1-84 [rDNA origin] injection). GATTEX is its analog of GLP-2, a protein involved in the regeneration and repair of the intestinal lining, and is in Phase 3 clinical development for parenteral dependent (PN) short bowel syndrome (SBS). SBS is a highly disabling condition that results from surgical resection, congenital defect or disease-associated loss of absorption and the subsequent inability to maintain fluid, electrolyte, and nutrient balances on a conventional diet. Natpara is the Company's recombinant full-length human parathyroid hormone (PTH 1-84) that is in Phase 3 clinical development for hypoparathyroidism, a rare condition in which the body does not maintain normal calcium levels in the blood due to insufficient levels of parathyroid hormone. The Company is currently advancing registration studies for GATTEX and Natpara. The Company has collaborations or royalty agreements with a number of pharmaceutical companies. 'NPS, 'NPS Pharmaceuticals', 'GATTEX', and 'PREOS' are the Company's trademarks. The Company has competitors in both the U.S. and internationally including multi-national pharmaceutical companies, chemical companies, biotech companies, universities and other research organizations. Many of its competitors have drug products that have already been approved or are in development, and operate large, well-funded research and development programs in these fields.
» More Articles for NPSP

Headlines

Articles On GuruFocus.com
Wedbush Weighs in on Medivation Following Phase II TERRAIN Study Results Feb 03 2015 
Shire Set To Acquire NPS Pharmaceuticals for $5.2 Billion Jan 15 2015 
Weekly CFO Sells Highlight: WRES, NPSP, MKTO, GRPN, RXN Sep 29 2013 
Weekly CFO Sells Highlight: KO, KKD, PIR, NPSP, ACAD Apr 16 2013 
NPS Pharmaceuticals Reports Second Quarter 2009 Financial Results; Two Phase 3 Registration Programs Aug 06 2009 
NPS Pharmaceuticals to Report Second Quarter Financial Results on August 6, 2009 Aug 03 2009 
NPS Pharmaceuticals Inc. Reports Operating Results (10-Q) May 05 2009 
George Soros Buys Partner Communications Co. Ltd, CR Bard Inc., Valley Forge Scientific Corp., Sells Aug 15 2006 

More From Other Websites
Shire (SHPG) Earnings Report: Q1 2015 Conference Call Transcript May 01 2015
Shire profits boosted by binge-eating drug Apr 30 2015
MDGN: Efficacy Through 10 Months, Add'l Studies Commencing Apr 22 2015
Magnetar Capital Lowers Its Stake in Shire Apr 14 2015
NPS PHARMACEUTICALS INC Financials Feb 27 2015
NPS PHARMACEUTICALS INC Files SEC form 8-K, Termination of a Material Definitive Agreement,... Feb 23 2015
NPS PHARMACEUTICALS INC Files SEC form 10-K, Annual Report Feb 18 2015
Will NPS Pharmaceuticals (NPSP) Miss on Earnings in Q4? - Analyst Blog Feb 16 2015
Shire Misses on Q4 Earnings, Revenues Beat; Shares Rise - Analyst Blog Feb 13 2015
Shire Moves Up On NPS Potential; Q4 Earnings Miss Feb 12 2015
Shire confident on 2015 after NPS deal, binge-eating drug approval Feb 12 2015
Shire confident on 2015 after NPS deal, binge-eating drug approval Feb 12 2015
Shire confident on 2015 after NPS deal, binge-eating drug approval Feb 12 2015
Shire sees mid-single earnings growth in 2015 Feb 12 2015
Shire sees mid-single earnings growth in 2015 Feb 12 2015
Shire's Vyvanse Label Expanded for Binge-Eating Disorder - Analyst Blog Feb 02 2015
Lifshitz & Miller Law Firm Announces Investigation of Calavo Growers, Inc., Courier Corporation,... Jan 29 2015
ETFs To Tap Into Greater M&A Activity Jan 28 2015
NPS Pharmaceuticals' Natpara Approved with Boxed Warning - Analyst Blog Jan 27 2015
NPS PHARMACEUTICALS INVESTOR ALERT: Faruqi & Faruqi, LLP Announces the Investigation of NPS... Jan 27 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK